Clinical Mass Spectrometry-Achieving Prominence in Laboratory Medicine

To provide readers with information about the current status of these issues, we have included a special report on the FDA perspectives on clinical MS (15 ), a special report from the Clinical Proteomic Tumor Analysis Consortium of the National Cancer Institute on consensus set of recommendations for peptide measurement (16 ), a perspective on CLSI C62-A as a new standard for clinical MS method development, evaluation, and validation (17), an opinion piece on the selectivity and specificity of MS (18), and a Q&A in which experts discuss their views on a variety of issues related to the use of MS (19). Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.